menu
    • menu
    [{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cholestyramine","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Pharmascience Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmascience Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avicanna \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/ Tetra BioPharma"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntelGenx \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Tetra BioPharma"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Dolcanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ BioFortis","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ BioFortis"},{"orgOrder":0,"company":"KGK Science","sponsor":"UAS Labs LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ UAS Labs LLC","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ UAS Labs LLC"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"AmacaThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AMT-143","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AmacaThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"AmacaThera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmacaThera \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Bifidobacterium Longum R0175","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KGK Science \/ Lallemand Health Solutions","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"KGK Science","sponsor":"Global Institute of Probiotics","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Digesta Lac","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Global Institute of Probiotics","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Global Institute of Probiotics"},{"orgOrder":0,"company":"KGK Science","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Litesse Powder Containing Polydextrose","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ International Flavors and Fragrances","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Thylakoid extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"ProbiSearch SL","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ ProbiSearch SL","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ ProbiSearch SL"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AmacaThera

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AmacaThera

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Postsurgical Analgesia After Hernia Repair

                            Details : AMT-143 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hernia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 29, 2024

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LALLEMAND HEALTH SOLUTIONS

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            LALLEMAND HEALTH SOLUTIONS

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : BioFortis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Probiotics on Infantile Colic Symptoms

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colic.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : BioFortis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avicanna

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Avicanna

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Tetra BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna

                            Details : The registration and commercialization of Tetra's various prescription products (REDUVO™ AdVersa®, QIXLEEF™ and CAUMZ™) across Avicanna's channels in Latin/South America. This opens the door for Tetra to initiate sales earlier than planned.

                            Product Name : Reduvo Adversa

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 14, 2022

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Tetra BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LALLEMAND HEALTH SOLUTIONS

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            LALLEMAND HEALTH SOLUTIONS

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : ProbiSearch SL

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Probiotics on Symptoms of Infantile Colic

                            Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of Colic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : ProbiSearch SL

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IntelGenx

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            IntelGenx

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Tetra BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive ...

                            Details : Tetra will use the Adversa® technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 21, 2020

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Tetra BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Devonian Health Group

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Devonian Health Group

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thylakoid extract

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Devonian Health Group Reports Notice of Allowance for a US Patent Application Covering Use of Thykamine for Ul...

                            Details : Devonian announced that the US Patent and Trademark Office has issued a Notice of Allowance for patent titled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease" covering the use of Thykamine™ for the treat...

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 15, 2020

                            Lead Product(s) : Thylakoid extract

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmascience Inc.

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome

                            Details : Cholestyramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 06, 2019

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bausch Health

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plecanatide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Consti...

                            Details : Plecanatide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 24, 2018

                            Lead Product(s) : Plecanatide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bausch Health

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Bausch Health

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plecanatide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Cons...

                            Details : Plecanatide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 19, 2017

                            Lead Product(s) : Plecanatide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            KGK Science

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            KGK Science

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Digesta Lac

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Global Institute of Probiotics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation

                            Details : Digesta Lac is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 22, 2015

                            Lead Product(s) : Digesta Lac

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Global Institute of Probiotics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth